A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder

Innovations in Clinical Neuroscience

Carl P. Gommoll¹  William M. Greenberg¹  Thomas Shiovitz¹  Changzheng Chen¹  Giovanna Forero¹ 

[1] Dr. Shiovitz with the California Neuroscience Research Medical Group Inc, Sherman Oaks, California; and Dr. Greenberg, Mr. Chen, Ms. Forero, and Mr. Gommoll are from Forest Research Institute, Jersey City, New Jersey.

关键词: Levomilnacipran;    antidepressants;    serotonin and norepinephrine reuptake inhibitor (SNRI);    major depressive disorder;    major depressive disorder relapse;   

DOI  :  

学科分类：精神健康和精神病学

来源: Matrix Medical Communications, LLC

【 摘 要 】

Objective: Major depressive disorder is often chronic, with relapse and recurrence common. Levomilnacipran extended-release is a potent and selective serotonin and reuptake inhibitor approved in the United States for treatment of major depressive disorder in adults. The objective of this study ({"type":"clinical-trial","attrs":{"text":"NCT01085812","term_id":"NCT01085812"}}NCT01085812) was to evaluate the efficacy, safety, and tolerability of levomilnacipran extended-release in the prevention of relapse in patients with major depressive disorder.

【 授权许可】

Unknown